Moody National Bank Trust Division Sells 917 Shares of Eli Lilly and Company $LLY

Key Points

• Moody National Bank Trust Division reduced its stake in Eli Lilly and Company by 7.8%, now holding 10,832 shares valued at approximately $8.44 million.
• Eli Lilly reported $6.31 EPS for the last quarter, exceeding analyst expectations of $5.59, with a year-over-year revenue increase of 37.6%.
• The company declared a quarterly dividend of $1.50 per share, amounting to a 0.8% yield based on its share price.

Moody National Bank Trust Division decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 7.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,832 shares of the company's stock after selling 917 shares during the quarter. Eli Lilly and Company makes up about 0.8% of Moody National Bank Trust Division's investment portfolio, making the stock its 22nd biggest holding. Moody National Bank Trust Division's holdings in Eli Lilly and Company were worth $8,444,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in LLY. WestEnd Advisors LLC raised its position in shares of Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after purchasing an additional 21 shares during the period. Wealth Preservation Advisors LLC bought a new position in shares of Eli Lilly and Company in the first quarter valued at about $27,000. Citizens National Bank Trust Department raised its position in shares of Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after purchasing an additional 27 shares during the period. Financial Gravity Asset Management Inc. bought a new position in shares of Eli Lilly and Company in the first quarter valued at about $40,000. Finally, Mascagni Wealth Management Inc. bought a new position in Eli Lilly and Company during the fourth quarter worth about $43,000. 82.53% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently commented on LLY. Leerink Partnrs lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. JPMorgan Chase & Co. lowered their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a research report on Tuesday, September 16th. Erste Group Bank lowered shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Leerink Partners reaffirmed a "market perform" rating and set a $715.00 price target on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Finally, Hsbc Global Res raised shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a report on Wednesday, August 27th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $939.61.

Insider Buying and Selling

In related news, CEO David A. Ricks bought 1,632 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the purchase, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Daniel Skovronsky bought 1,000 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the purchase, the executive vice president owned 137,660 shares of the company's stock, valued at $87,331,504. This represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 4,514 shares of company stock worth $2,894,841. Corporate insiders own 0.14% of the company's stock.

Eli Lilly and Company Trading Up 0.4%

NYSE:LLY traded up $3.33 during mid-day trading on Monday, hitting $755.32. 2,524,436 shares of the company's stock were exchanged, compared to its average volume of 3,388,311. The company has a 50 day simple moving average of $737.49 and a 200-day simple moving average of $769.01. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $939.30. The firm has a market capitalization of $714.88 billion, a P/E ratio of 49.37, a PEG ratio of 1.05 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period last year, the company earned $3.92 EPS. The firm's revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.